David Lebowitz
Stock Analyst at Citigroup
(2.41)
# 2,409
Out of 4,711 analysts
98
Total ratings
46.48%
Success rate
-0.69%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Sell | $26 → $32 | $46.24 | -30.80% | 3 | Dec 4, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $41.51 | +63.82% | 4 | Nov 13, 2024 | |
| INCY Incyte | Maintains: Buy | $92 → $97 | $68.84 | +40.91% | 4 | Oct 30, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $25 → $19 | $12.18 | +55.99% | 6 | Oct 25, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $70 | $25.14 | +178.44% | 1 | Oct 7, 2024 | |
| COGT Cogent Biosciences | Maintains: Buy | $13 → $15 | $7.84 | +91.33% | 3 | Sep 24, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $178 → $207 | $136.38 | +51.78% | 12 | Sep 17, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Buy | $45 → $44 | $13.21 | +233.08% | 4 | May 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Sell | $65 → $76 | $90.14 | -15.69% | 5 | May 3, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $39 → $37 | $19.44 | +90.33% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $308.44 | +23.85% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $46 | $26.49 | +73.65% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $33.29 | -6.88% | 1 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 → $60 | $35.63 | +68.40% | 11 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $65.66 | +46.21% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $2.00 | +500.00% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $245.44 | -33.18% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $14.99 | +160.17% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $13.08 | +60.55% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $0.64 | +4,151.97% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $4.45 | +214.61% | 2 | Oct 12, 2021 |
PTC Therapeutics
Dec 4, 2024
Maintains: Sell
Price Target: $26 → $32
Current: $46.24
Upside: -30.80%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $41.51
Upside: +63.82%
Incyte
Oct 30, 2024
Maintains: Buy
Price Target: $92 → $97
Current: $68.84
Upside: +40.91%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $25 → $19
Current: $12.18
Upside: +55.99%
Celldex Therapeutics
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $25.14
Upside: +178.44%
Cogent Biosciences
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.84
Upside: +91.33%
Ascendis Pharma
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $136.38
Upside: +51.78%
Pliant Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $45 → $44
Current: $13.21
Upside: +233.08%
Blueprint Medicines
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $90.14
Upside: -15.69%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $19.44
Upside: +90.33%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $308.44
Upside: +23.85%
Feb 23, 2024
Maintains: Buy
Price Target: $42 → $46
Current: $26.49
Upside: +73.65%
Dec 15, 2023
Initiates: Buy
Price Target: $31
Current: $33.29
Upside: -6.88%
Jul 31, 2023
Upgrades: Buy
Price Target: $36 → $60
Current: $35.63
Upside: +68.40%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $65.66
Upside: +46.21%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $2.00
Upside: +500.00%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $245.44
Upside: -33.18%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $14.99
Upside: +160.17%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $13.08
Upside: +60.55%
Oct 12, 2021
Maintains: Overweight
Price Target: $29 → $27
Current: $0.64
Upside: +4,151.97%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $4.45
Upside: +214.61%